Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Privatdozent/in, Klinik für Dermatologie
Aktuelle Veranstaltungen
-
SoSe 2025
Vergangene Veranstaltungen (max. 10)
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
-
SoSe 2023
-
WiSe 2022
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cellsIn: OncoTarget , Jg. 16 2025, S. 257 – 259DOI (Open Access)
-
RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanomaIn: Clinical and Translational Medicine , Jg. 15 2025, Nr. 1, e70094DOI (Open Access)
-
SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cellsIn: Frontiers in Immunology , Jg. 15 2025, 1490821DOI (Open Access)
-
Single-cell transcriptomics and epigenomics point to CD58-CD2 interaction in controlling primary melanoma growth and immunityIn: Cancer Communications , Jg. 45 2025, Nr. 4, S. 465 – 470DOI (Open Access)
-
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapyIn: European Journal of Cancer (EJC) , Jg. 220 2025, 115337DOI (Open Access)
-
A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanomaIn: Cell , Jg. 187 2024, Nr. 1, S. 166 – 183.e25DOI (Open Access)
-
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanomaIn: Frontiers in Immunology , Jg. 15 2024, 1383125DOI (Open Access)
-
Early versus late response to PD-1-based immunotherapy in metastatic melanomaIn: European Journal of Cancer (EJC) , Jg. 210 2024, 114295DOI (Open Access)
-
Long non-coding RNA GRASLND links melanoma differentiation and interferon-gamma responseIn: Frontiers in Molecular Biosciences , Jg. 11 2024, 1471100DOI (Open Access)
-
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer : A randomized phase 2 trialIn: Nature Medicine , Jg. 30 2024, Nr. 6, S. 1602 – 1611DOI (Open Access)
-
Orthanq: transparent and uncertainty-aware haplotype quantification with application in HLA-typingIn: BMC Bioinformatics , Jg. 25 2024, Nr. 1, 240DOI (Open Access)
-
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasIn: European Journal of Cancer (EJC) , Jg. 208 2024, 114208DOI (Open Access)
-
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer , Jg. 4 2023, Nr. 9, S. 1395DOI (Open Access)
-
Cytotoxic CD4⁺ T cells in chronic viral infections and cancerIn: Frontiers in Immunology , Jg. 14 2023, 1271236DOI, Online Volltext (Open Access)
-
Database for queries of melanoma cohorts with molecular and clinical dataIn: Pigment Cell and Melanoma Research , Jg. 36 2023, Nr. 2, S. 252 – 258DOI (Open Access)
-
HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistanceIn: Clinical Cancer Research , Jg. 29 2023, Nr. 15, S. 2894 – 2907
-
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer , Jg. 4 2023, Nr. 9, S. 1292 – 1308DOI (Open Access)
-
MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associatedIn: Frontiers in Cell and Developmental Biology , Jg. 10 2023, 1055288DOI (Open Access)
-
Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cellsIn: Biomedicine & Pharmacotherapy , Jg. 168 2023, 115635DOI (Open Access)
-
Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptorsIn: Frontiers in Immunology , Jg. 14 2023, 1245559DOI (Open Access)
-
Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptorsIn: Frontiers in Immunology , Jg. 14 2023, 1119498DOI (Open Access)
-
Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint BlockadeIn: Annual Review of Cancer Biology , Jg. 6 2022, S. 85 – 102DOI (Open Access)
-
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotypeIn: Clinical and Translational Medicine , Jg. 12 2022, Nr. 11, e1090DOI, Online Volltext (Open Access)
-
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalIn: Cancers , Jg. 14 2022, Nr. 9, 2090DOI, Online Volltext (Open Access)
-
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsIn: Cancers , Jg. 14 2022, Nr. 17, 4066DOI, Online Volltext (Open Access)
-
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsIn: International Journal of Cancer , Jg. 151 2022, Nr. 9, S. 1542 – 1554DOI (Open Access)
-
Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicityIn: Journal for ImmunoTherapy of Cancer , Jg. 10 2022, Nr. 6, e003863DOI (Open Access)
-
Persister state-directed transitioning and vulnerability in melanoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Nature Communications , Jg. 13 2022, Nr. 1, S. 35 – 36DOI, Online Volltext (Open Access) -
Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expressionIn: Nature Communications , Jg. 13 2022, Nr. 1, 156DOI (Open Access)
-
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyIn: European Journal of Cancer (EJC) , Jg. 161 2022, S. 99 – 107DOI (Open Access)
-
Expression of potential targets for cell-based therapies on melanoma cellsIn: Life , Jg. 11 2021, Nr. 4, S. 269DOI (Open Access)
-
GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular TumorsIn: Frontiers in Genetics , Jg. 12 2021, 663272DOI, Online Volltext (Open Access)
-
Innate RIG-I signaling restores antigen presentation in tumors and overcomes T cell resistanceIn: Cell Stress: The Journal of the European Research Institute for Integrated Cellular Pathology , Jg. 5 2021, Nr. 2, S. 26 – 28DOI (Open Access)
-
Melanoma Differentiation Trajectories Determine Sensitivity Toward Pre-Existing CD8⁺ Tumor-Infiltrating LymphocytesIn: Journal of Investigative Dermatology , Jg. 141 2021, Nr. 10, S. 2480 – 2489DOI (Open Access)
-
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer (EJC) , Jg. 148 2021, S. 340 – 347DOI (Open Access)
-
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsIn: European Journal of Cancer (EJC) , Jg. 159 2021, S. 113 – 124
-
The predictive and prognostic significance of cell-free DNA concentration in melanomaIn: Journal of the European Academy of Dermatology and Venereology , Jg. 35 2021, Nr. 2, S. 387 – 395DOI (Open Access)
-
Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma RegressionIn: Frontiers in Immunology , Jg. 11 2020, S. 1849DOI, Online Volltext (Open Access)
-
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine , Jg. 26 2020, Nr. 7, S. 1147DOI (Open Access)
-
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathologyIn: PLoS Pathogens , Jg. 16 2020, Nr. 3, e1008340DOI (Open Access)
-
ER-aminopeptidase 1 determines the processing and presentation of an immunotherapy-relevant melanoma epitopeIn: European Journal of Immunology , Jg. 50 2020, Nr. 2, S. 270 – 283DOI (Open Access)
-
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanomaIn: Annals of Oncology , Jg. 31 2020, Nr. 1, S. 144 – 152DOI (Open Access)
-
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyIn: The Journal of Clinical Investigation (JCI) , Jg. 130 2020, Nr. 8, S. 4266 – 4281DOI (Open Access)
-
Chronic retroviral infection of mice promotes tumor development, but CD137 agonist therapy restores effective tumor immune surveillanceIn: Cancer Immunology, Immunotherapy , Jg. 68 2019, Nr. 3, S. 479 – 488DOI (Open Access)
-
Clinical and genetic analysis of melanomas arising in acral sitesIn: European Journal of Cancer (EJC) , Jg. 119 2019, S. 66 – 76DOI (Open Access)
-
Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cellsIn: International Journal of Cancer , Jg. 144 2019, Nr. 7, S. 1645 – 1656
-
Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53In: Theranostics , Jg. 9 2019, Nr. 21, S. 6047 – 6062DOI (Open Access)
-
Frequent Occurrence of NRAS and BRAF Mutations in Human Acral NaeviIn: Cancers , Jg. 11 2019, Nr. 4, S. 546DOI, Online Volltext (Open Access)
-
High PD-1 or PD-L1 Concentrations in the Serum of Melanoma Patients are predictive for reduced Therapeutic Success of PD-1 InhibitionIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 17 2019, Nr. Suppl. 5, S. 7 – 7
-
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine , Jg. 25 2019, Nr. 12, S. 1916 – 1927DOI (Open Access)
-
The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in MelanomaIn: Cell Reports , Jg. 27 2019, Nr. 12, S. 3573 – 3586.e7DOI (Open Access)
-
Evolution of melanoma cross-resistance to CD8⁺ T cells and MAPK inhibition in the course of BRAFi treatmentIn: OncoImmunology , Jg. 7 2018, Nr. 8, e1450127DOI (Open Access)
-
Immunoassays for scarce tumour-antigens in exosomes : Detection of the human NKG2D-Ligand, MICA, in tetraspanin-containing nanovesicles from melanomaIn: Journal of Nanobiotechnology , Jg. 16 2018, Nr. 1, S. 47DOI (Open Access)
-
Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitorsIn: OncoImmunology , Jg. 7 2018, Nr. 2, e1392426DOI (Open Access)
-
NF1 mutations in conjunctival melanomaIn: British Journal of Cancer (BJC) , Jg. 118 2018, Nr. 9, S. 1243 – 1247DOI (Open Access)
-
Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy ResistanceIn: Journal of the National Cancer Institute (JNCI) , Jg. 110 2018, Nr. 6, S. 677 – 681DOI (Open Access)
-
Acquired IFNγ 3 resistance impairs anti-Tumor immunity and gives rise to T-cell-resistant melanoma lesionsIn: Nature Communications , Jg. 8 2017, 15440DOI (Open Access)
-
Activated Tissue-Resident Mesenchymal Stromal Cells Regulate Natural Killer Cell Immune and Tissue-Regenerative FunctionIn: Stem Cell Reports , Jg. 9 2017, Nr. 3, S. 985 – 998DOI (Open Access)
-
Activated tissue-resident mesenchymal stromal cells regulate natural killer cell immune and tissue regenerative functionIn: European Journal of Immunology , Jg. 47 2017, Nr. S2, Special Issue:47th Annual Meeting of the German Society for Immunology, 12–15 September, 2017, Erlangen, Germany, S. 62
-
Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue neviIn: Modern Pathology , Jg. 30 2017, Nr. 3, S. 350 – 356DOI (Open Access)
-
Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinomaIn: Scientific Reports , Jg. 7 2017, Nr. 1, S. 2290DOI (Open Access)
-
Fas Ligand-mediated cytotoxicity of CD4+ T cells during chronic retrovirus infectionIn: Scientific Reports , Jg. 7 2017, S. 7785DOI (Open Access)
-
Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris MelanomaIn: Investigative Ophthalmology & Visual Science, IOVS , Jg. 58 2017, Nr. 9, S. 3464 – 3470DOI (Open Access)
-
HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma modelIn: OncoTarget , Jg. 8 2017, Nr. 17, S. 28312 – 28327DOI (Open Access)
-
SF3B1 and BAP1 mutations in blue nevus-like melanomaIn: Modern Pathology , Jg. 30 2017, Nr. 7, S. 928 – 939DOI (Open Access)
-
The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformationIn: Oncogene , Jg. 36 2017, Nr. 36, S. 5110 – 5121
-
Development of a rapid lateral flow immunoassay test for detection of exosomes previously enriched from cell culture medium and body fluidsIn: Journal of Extracellular Vesicles (JEV) , Jg. 5 2016, Nr. 1, S. 31803DOI (Open Access)
-
Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS)In: Scientific Reports , Jg. 6 2016, S. 25208DOI (Open Access)
-
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic LatencyIn: Cancer Research , Jg. 76 2016, Nr. 15, S. 4347 – 4358
-
Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanomaIn: European Journal of Cancer (EJC) , Jg. 59 2016, S. 109 – 112
-
The Influence of HLA and KIR Genes on Malignant Melanoma Development and ProgressionIn: Archivum Immunologiae et Therapiae Experimentalis , Jg. 64 2016, Nr. Suppl. 1, S. 73 – 81
-
Analysis of SDHD promoter mutations in various types of melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 13 2015, Nr. Suppl. 2, S. 11
-
Analysis of SDHD promoter mutations in various types of melanomaIn: OncoTarget , Jg. 6 2015, Nr. 28, S. 25868 – 25882DOI (Open Access)
-
Deciphering the genetic evolution of T-cell resistance in melanomaIn: OncoImmunology , Jg. 4 2015, Nr. 5, e1005510DOI (Open Access)
-
Frequent TERT Promoter Mutations in Ocular Surface Squamous NeoplasiaIn: Investigative Ophthalmology & Visual Science, IOVS , Jg. 56 2015, Nr. 10, S. 5854 – 5861DOI (Open Access)
-
The proteasome immunosubunits, PA28 and ER-aminopeptidase 1 protect melanoma cells from efficient MART-126-35-specific T-cell recognitionIn: European Journal of Immunology , Jg. 45 2015, Nr. 12, S. 3257 – 3268DOI (Open Access)
-
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaIn: Annals of Oncology , Jg. 25 2014, Nr. 3, S. 747 – 753
-
Expression of stress ligands of the immunoreceptor NKG2D in melanoma : regulation and clinical significanceIn: European Journal of Cell Biology (EJCB) , Jg. 93 2014, Nr. 1-2, S. 49 – 54
-
Genetic evolution of T-cell resistance in the course of melanoma progressionIn: Clinical Cancer Research , Jg. 20 2014, Nr. 24, S. 6593 – 6604
-
Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30In: Cancer Research , Jg. 74 2014, Nr. 13, S. 3429 – 3440
-
Dacarbazine in melanoma: From a chemotherapeutic drug to an immunomodulating agentIn: Journal of Investigative Dermatology , Jg. 133 2013, Nr. 2, S. 289 – 292DOI (Open Access)
-
Immunological consequences of selective BRAF inhibitors in malignant melanoma : Neutralization of myeloid-derived suppressor cellsIn: OncoImmunology , Jg. 2 2013, Nr. 8, e25218DOI (Open Access)
-
New developments in biomarkers for melanomaIn: Current Opinion in Oncology , Jg. 25 2013, Nr. 2, S. 145 – 151
-
Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cellsIn: The American Journal of Pathology , Jg. 182 2013, Nr. 6, S. 2121 – 2131
-
Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsIn: Cancer Research , Jg. 73 2013, Nr. 8 Suppl., S. 4714
-
Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsIn: International Journal of Cancer , Jg. 133 2013, Nr. 7, S. 1653 – 1663
-
Gegen den Hautkrebs : Forschung zur Überwindung immuntherapeutischer Hürden beim malignen MelanomIn: Unikate: Berichte aus Forschung und Lehre 2012, Nr. 42: Translationale Krebsforschung: Auf dem Weg zu neuen Therapien, S. 32 – 41DOI, Online Volltext (Open Access)
-
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypesIn: Cancer Immunology, Immunotherapy , Jg. 61 2012, Nr. 9, S. 1359 – 1371
-
The efficiency of human cytomegalovirus pp65₄₉₅₋₅₀₃ CD8 ⁺T cell epitope generation is determined by the balanced activities of cytosolic and endoplasmic reticulum-resident peptidasesIn: The Journal of Immunology (JI) , Jg. 189 2012, Nr. 2, S. 529 – 538
-
Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2DIn: Cancer Research , Jg. 72 2012, Nr. 2, S. 460 – 471
-
Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2DIn: OncoImmunology , Jg. 1 2012, Nr. 4, S. 535 – 536
-
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopesIn: Nature Immunology , Jg. 12 2011, Nr. 1, S. 45 – 53
-
Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumorsIn: Immunogenetics , Jg. 63 2011, Nr. 2, S. 65 – 71
-
Adoptive T-Zell-Therapie des RhabdomyosarkomsIn: Der Pathologe , Jg. 31 2010, Nr. SUPPL. 2, S. 215 – 220
-
MMP19 is upregulated during melanoma progression and increases invasion of melanoma cellsIn: Modern Pathology , Jg. 23 2010, Nr. 4, S. 511 – 521
-
Multicentre study on standardisation of melanoma cell culture : An initiative of the German Melanoma Research NetworkIn: Pigment Cell and Melanoma Research , Jg. 23 2010, Nr. 2, S. 296 – 298
-
Screening of Human Tumor Antigens for CD4+ T Cell Epitopes by Combination of HLA-Transgenic Mice, Recombinant Adenovirus and Antigen Peptide LibrariesIn: PLoS ONE , Jg. 5 2010, Nr. 11, S. e14137DOI (Open Access)
-
RECQL4-mediated Downregulation of MHC Class II promotes Immune Evasion and reduced Anti-PD-1 Response in Melanoma PatientsIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 6
-
GSK3-beta activation is a key driver of resistance to RAF inhibition in BRAF mutant melanoma cellsIn: Experimental Dermatology , Jg. 32 2023, Nr. 4, S. e30
-
Molekulare und klinische Charakterisierung von BRAF/NRAS/NF1-wt Melanomen
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21DOI (Open Access) -
Untersuchung des klinischen Verlaufs von Melanompatienten mit einer Super-Response (CR/PR innerhalb von 3 Monaten) unter PD-1-basierter Immuncheckpoint-Inhibition : eine Subgruppen-Analyse der prospektiven multizentrischen Studie ADOREG
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 8 – 9DOI (Open Access) -
Using CRISPitope (CRISPR-assisted insertion of epitopes) to study T cell responses against human melanoma cellsIn: Experimental Dermatology 2023, S. e102
-
Compartment-based proteomics of CD8high vs. CD8low melanoma regions reveals differential regulation of TOR signaling
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 12 -
Im Plasma zirkulierende zellfreie mRNA ermöglicht die minimal-invasive und Genotyp-unabhängige Therapieüberwachung bei Patienten mit Melanom
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 12 – 13 -
Interferon-independent enhancement of melanoma cell immunogenicity by RIG-I activation
47th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) Virtual, March 04‐06, 2021,In: Experimental Dermatology , Jg. 30 2021, Nr. 3, S. E78 -
Intratumoral Immunotherapy : RIG-I Agonists induce a dedifferentiated yet T-Cell-sensitive Melanoma Cell PhantotypeIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 34
-
Profiling of tumor-infiltrating T cells for guidance of melanoma salvage therapy in immune-checkpoint-blockade resistant patients
47th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) Virtual, March 04‐06, 2021,In: Experimental Dermatology , Jg. 30 2021, Nr. 3, S. E52 -
TERT Promoter Mutations associated with longer progression-free and Overall Survival under BRAF/MEK TherapyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 31
-
Distinct melanoma differentiation trajectories driven by MAPKi associate with activation of CD8+tumor-infiltrating lymphocytesIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV17DOI (Open Access)
-
RIG-I activation enhances melanoma immunogenicity and improves anti-tumor T cell responses in combination with anti-PD-1 immune checkpoint blocking antibodiesIn: Journal for ImmunoTherapy of Cancer , Jg. 8 2020, Nr. Suppl. 2, S. A3DOI (Open Access)
-
Tumorzell‐intrinsiche Aktivierung des Immunrezeptors RIG‐I in Kombination mit Immun‐Checkpoint‐Blockade verbessert anti‐Tumor T‐ZellantwortenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV18DOI (Open Access)
-
Impact of T cells transduced with an HLA-independent T-cell receptor (TCR) against the alpha chain of the GM-CSF receptor (CSF2RA) on hematopoietic progenitor cells
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment , Jg. 42 2019, Nr. Supplement 4: Abstracts, S. 99DOI (Open Access) -
Evolution of cross‐resistance to CD8+ T cells in the course of BRAF and MEK inhibitor treatment in BRAFV600E melanoma
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. 6, S. 53DOI (Open Access) -
Optogenetic stimulation of Lbc GEF-mediated Rho activity dynamics promotes cell invasion2025DOI (Open Access)
-
Redirecting resistance evolution in BRAFV600 melanoma by inhibition of the peroxiredoxin-thioredoxin system2025DOI (Open Access)
-
The era of checkpoint inhibition : Lessons learned from melanomaIn: Current Immunotherapeutic Strategies in Cancer / Theobald, Matthias (Hrsg.) 2020, S. 169 – 187
-
Role of IFNγ-induced tumor-T cell equilibrium in melanoma latencyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 34DOI (Open Access)
-
Genetic and methylation analysis of CTNNB1 mutations in benign and malignant melanocytic lesions
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 84 -
Liquid biopsy for the detection of HLA-I alterations in cancer
Joint 35th European Immunogenetics and Histocompatibility Conference; May 17–20, 2022; Amsterdam, the Netherlands,In: HLA: Immune Response Genetics (Human Leukocyte Antigens) , Jg. 99 2022, Nr. 5, SI, S. 430 -
Molekularpathologie und Methylierungsprofile als diagnostische Unterstützung zur Differenzierung von Klarzellsarkomen und melanozytären Tumoren
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 88 -
Persister state-directed transitioning and vulnerability in melanoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 35 – 36